on behalf of the Spanish Sleep Network * BACKGROUND: Evidence from longitudinal studies has reported contradictory results regarding the association between OSA and hypertension. In a previous analysis of the Vitoria Sleep Cohort, the relationship between OSA and the risk of developing hypertension was evaluated and no independent association after adjustment for confounding factors was found. In the present study, a post hoc analysis to assess the association between OSA and incident stage 2 hypertension (systolic BP $ 160 mm Hg and/or diastolic BP $ 100 mm Hg) was made on the basis of sex differences.
Evidence from several cross-sectional studies [1] [2] [3] suggests an association between OSA and hypertension; however, conflicting results have emerged from prospective studies [4] [5] [6] [7] and, currently, the pathophysiological interactions between OSA and hypertension are not completely understood. Evidence of an association between OSA and hypertension is also indicated by several intervention trials, in which CPAP was shown to reduce BP [8] [9] [10] or in which CPAP withdrawal resulted in a clinically relevant increase in BP. 11 However, this improvement in BP control is not equally observed in all patients with OSA on CPAP treatment, suggesting the occurrence of different OSA subgroups. Studies performed on subjects without daytime sleepiness have failed to show a significant effect of CPAP on BP, 12, 13 and other studies reported only a minor BP reduction in normotensive subjects, 14, 15 a modest reduction in patients with hypertension, 16 or no significant effect in resistant hypertension, 17 whereas others have shown a significant BP reduction in patients with severe or refractory hypertension. 18, 19 We evaluated in a previous analysis of the Vitoria Sleep Cohort the relationship between OSA and the risk of developing hypertension; the findings did not suggest an independent association between OSA and the incidence of hypertension, and revealed no sex differences. 6 In the present study, a post hoc analysis was performed to assess the relationship between OSA and the risk of developing moderate to severe hypertension, which corresponds to grade 2 and 3 in the European Task Force for the management of arterial hypertension 20 and to stage 2 in the American guidelines. 21 This stage has at least a moderate 10-year risk of cardiovascular mortality and, for this reason, current guidelines recommend treating these patients with antihypertensive treatment regardless of the presence of other cardiovascular risk factors. 20 Recent guidelines have also underlined the paucity of data for treating grade 1 hypertension, 22 recommending treatment only after confirming hypertension by ambulatory BP monitoring (ABPM) and restricting treatment to patients with grade 1 hypertension and signs of organ damage or at high total cardiovascular risk.
Methods

Study Design and Patients
Details of the study design have been previously published. 6, 23 Briefly, it is a prospective study performed over 7.5 AE 0.8 years on the middleaged (30-70 years) general population of the Vitoria Sleep Cohort to assess the association between OSA and hypertension. This cohort enrolled a group of 1,521 subjects who met the inclusion criteria for the cross-sectional baseline study 23 and underwent a structured interview that included sleep questionnaires, a physical examination with anthropometric and BP measurements, and a nocturnal polygraphy. At the end of the monitoring period, BP was measured again. The exclusion criteria for the present study included subjects treated with CPAP or uvulopalatopharyngoplasty and subjects who had hypertension at baseline. The main objective of the present study was to assess the association between OSA and the risk of developing more clinically significant hypertension (ie, moderate to severe hypertension) and to evaluate sex differences.
The study was approved by the OSI Araba Hospital Ethics Committee (approval No. 2010-027) and written informed consent was obtained from all patients.
Study Variables
An unattended at-home polygraphy (MESAM IV; Medizintechnik für Artz und Patient) 24 was performed for all participants to classify the population according to the respiratory disturbance index (RDI). In these analyses, the RDI was divided into subgroups (0-2.9, 3-6.9, 7-13.9, and $14/h), using the first subgroup as reference.
BP was measured at the beginning and at the end of the study with a mercury sphygmomanometer following standard recommendations. 25 Hypertension was defined as systolic BP (SBP) $ 140 mm Hg and/ or diastolic BP (DBP) $ 90 mm Hg or current treatment with antihypertensive medications and was classified in three grades following standard guidelines:
20 grade 1 included all subjects with SBP ¼ 140 to 159 mm Hg and/or DBP ¼ 90 to 99 mm Hg; grade 2 included subjects with SBP ¼ 160 to 179 mm Hg and/or DBP ¼ 100 to 109 mm Hg; and grade 3 included subjects with SBP $ 180 mm Hg and/or DBP $ 110 mm Hg. For this study, the patients were classified in two stages: stage 1 corresponded to mild hypertension and included all subjects with grade 1 hypertension and stage 2 corresponded to moderate-to-severe hypertension and included all subjects with grade 2 or 3 hypertension or those on current treatment with antihypertensive medications.
Excessive daytime sleepiness (EDS) was defined as sleepiness occurring at least 3 or more days a week during the past 3 months under one or more of the following conditions: after waking, during free time (leisure time), at work or driving, or during daytime in general according to the Basic Nordic Sleep Questionnaire. 26 
Statistical Analysis
Univariate associations with hypertension after follow up were assessed using the Mann-Whitney U test for continuous variables and Fisher exact test for categorical variables. Logistic regression models were used to determine the association between RDI and stage 2 hypertension incidence. Age, sex, BMI, and neck circumference were included in the adjusted models because they were significantly associated on the basis of univariate analysis (e- Table 1 ). A recursive partitioning method (AnswerTree Software for SPSS Inc) was used to determine the variables that were related to stage 2 hypertension incidence. The tree-building process involved the variables: age, sex, BMI, neck circumference, and RDI. Recursive partitioning identified the threshold value for each variable that provided the best separation for identifying stage 2 hypertension with the highest purity, except for the BMI variable, which was previously categorized in two groups: BMI < 30 kg/m 2 and BMI $ 30 kg/m 2 . The variable that achieved the most precise separation of patients with and without stage 2 hypertension was chestjournal.org selected as the best predictor for the first branch of the tree. The recursive partitioning procedure was repeated for the two subgroups resulting from each split until reaching a subgroup that contained fewer than 25 patients or was more than three levels deep. Logistic regression analyses were used to estimate the ORs for stage 2 hypertension within each subgroup defined according to the previous tree and in reference to the subgroup with the lowest prevalence of stage 2 hypertension. All statistical analyses were performed using IBM SPSS, version 23.0 (SPSS Inc) or R, 27 with a significance level of .05.
Results
The flow chart of the patients included in the study is depicted in Figure 1 and the main characteristics of the patients who were normotensive at baseline are presented in Table 1 . These subjects were middle-aged and normoweight on average. Almost one-fifth of the population had excessive daytime sleepiness and a high percentage of participants reported smoking and alcohol consumption. More than two-thirds of the women were premenopausal according to their average age. The presence of severe sleep apnea was very low (1.6%) and moderate to severe sleep apnea was higher in men than in women. Men also showed a higher cumulative time percentage of oxygen saturation <90% (CT90) than women. After 7.5 AE 0.8 years of follow-up (Table 2) , the incidence of hypertension in the general sample was 33%, and 90 (23%) of these patients developed stage 2 hypertension. In addition, a statistically significant difference in the stage 2 hypertension incidence was observed between men and women (13.7% and 3.2%, respectively; P < .001). Almost three-quarters (72%) of the subjects who developed stage 2 hypertension were on antihypertensive medication, with this percentage being higher in women than in men (86% vs 68% respectively, P < .001).
The relationship between the baseline RDI and final hypertension stage for patients who were normotensive at baseline is presented in Figure 2 . Differences were not observed in the baseline RDI between the subjects who developed stage 1 hypertension and the subjects who remained normotensive (median RDI of 4/h). However, a significant difference was observed in the baseline RDI between both groups and the group that developed stage 2 hypertension (median RDI of 8/h and Bonferroni adjusted P value < .0001 for both comparisons).
The association between the baseline RDI and the incidence of stage 2 hypertension is presented in Table 3 . The OR significantly increased with higher RDI categories and after controlling for age, sex, BMI, and neck circumference (at RDI $14; OR, 2.51 [95% CI, 1.18-5.33]; overall P trend ¼ .017).
The association between the baseline RDI and the risk of developing stage 2 hypertension stratified by sex (Table 4 ) was also examined because of the significant interactions of sex with neck circumference (P ¼ .047) and age (P ¼ .028), with the same variables controlled for except sex. In the case of men, a baseline RDI $ 14 was associated with a significantly increased OR for the development of stage 2 hypertension (OR, 2.54 [95% CI, 1.09-5.95], overall P trend ¼ .032). This association was not statistically significant among women (overall P trend ¼ .371), although the OR for women increased with higher RDI categories.
The relationship between the RDI categories and the incidence of hypertension was also evaluated considering the presence or absence of EDS. The OR did not significantly increase with higher RDI categories in subjects with EDS (crude OR, P ¼.228) or in subjects without EDS (crude OR, P ¼ .102). These results were also confirmed by the absence of statistical significance in the interaction between the RDI and sleepiness (P value for interaction ¼ .653).
A decision tree of risk factors for incident stage 2 hypertension was constructed according to the recursive partitioning method and is presented in Figure 3 , and the probability of developing stage 2 hypertension in each subgroup is shown in Table 5 . Seven risk subgroups were noted on the basis of the following risk variables (which had their own threshold values): age, sex, BMI, neck circumference, and RDI. OR of presenting stage 2 hypertension was estimated using the subgroup with the lowest stage 2 hypertension incidence (women who were nonobese and # 56 years of age) was the reference. An RDI $ 14/h was the main risk factor for hypertension incidence in men but not in women (OR in men ¼ 25.33 [95% CI, 9.76-65.73] P < .001, with an incidence of 22.6% of stage 2 hypertension). In the case of women, OSA presence was not a significant risk factor for stage 2 hypertension development. The majority of women in the sample (81%) belonged to the lowest risk subgroup for stage 2 hypertension incidence (young and nonobese women), although there was a subgroup of women (3.8%) (older than 56 years with a neck circumference diameter > 35.3 cm) who had the highest stage 2 hypertension incidence of the sample (28.0%) (OR, 33.70 [95% CI, 10.28-110.50], P < .001), regardless of their RDI.
Discussion
The post hoc analysis suggests an association between moderate to severe OSA and the risk of developing more severe forms of hypertension in middle-aged men in the general population after 7.5 years of follow-up. Men with an RDI $ 14/h exhibited a 2.5-fold increased risk of developing stage 2 hypertension compared with those without OSA. In women, this relationship was not statistically significant. An analysis of the risk subgroups for stage 2 hypertension incidence confirmed this sex difference and showed that moderate to severe OSA was the main risk factor for hypertension development in men. EDS did not appear to modify this relationship. hypertension but did not determinate the incidence of both stages of hypertension because they could not precisely identify the participants who were normotensive at baseline and the different grades of hypertension of those on current treatment with antihypertensive medications.
To the best of our knowledge, this is the first attempt to explore different clinical subgroups related to hypertension incidence using the recursive partitioning method. The objective was to explore all risk factors for developing stage 2 hypertension to identify clinical subgroups and provide insights into the association between OSA and hypertension. In addition to the RDI, age was a clinically and statistically significant risk factor for both sexes (although the cutoff point was different), and neck circumference and BMI were clinical variables that identified different risk subgroups only in women. In recent years, several studies have attempted to identify different OSA subgroups using a different statistical approach: the cluster analysis. Ye and et al 28 identified three distinct clusters and demonstrated an increased probability of hypertension in minimally symptomatic patients compared with those with EDS. In a recent paper, Lacedonia et al 29 also identified three different subgroups of patients with OSA, which were those who belonged to the cluster with higher apneahypopnea index and higher nocturnal hypoxemia and those who presented the highest prevalence of hypertension. In this study, neither symptoms (EDS) nor nocturnal hypoxia, which were assessed by CT90 and the oxygen desaturation index, were independently associated with incident hypertension.
The slight association between OSA and stage 2 hypertension observed in women in this study could be related to several factors: mainly, the small number of women with an RDI $ 14/h and with stage 2 hypertension in the sample; the high proportion of premenopausal (67.4%) and consequently young women (44.4 AE 9.6 years), a status with lower prevalence of OSA and hypertension 30 ; the lower BMI for women compared with men (24.1 AE 3.7 kg/m 2 vs 26.0 AE 3.0 kg/m 2 , respectively, P < .001); and, finally, the lower Regarding daytime sleepiness, conflicting results have emerged. 28, 36 In this study, EDS did not appear to modify this relationship. Consistent with these results, Marin et al 7 did not find an association between the Epworth Sleepiness Scale score and the incidence of hypertension in patients with OSA who were not treated with CPAP. The discrepancies observed between this study and other studies could be related to the sample population (general population vs sleep-disorder clinics) or the different methods used to assess sleepiness (Basic Nordic Sleep Questionnaire, which is a questionnaire that has been widely used and shown to be a valid tool for epidemiological and genetic research for OSA, was used in this study). 37 Our study presented a number of potential limitations. Office BP measurements were used instead of 24-hour ABPM; however, the use of office BP measurements has been validated in several studies and is recommended as the screening method for hypertension assessments, 21 whereas ABPM is costly and time consuming when performed on a large population. Another potential limitation is that polysomnography was not performed on all subjects. However, the data obtained for participants who underwent both polygraphy and polysomnography did not show any significant differences in the association between OSA and hypertension. 23 Finally, the majority of the general population had mild to moderate sleep apnea; therefore, patients with severe OSA were not well represented. This is especially relevant in the case of women, because the small number of women with an RDI $ 14/h and with stage 2 hypertension incidence may reflect low study power rather than a lack of statistical significance for the association between OSA and stage 2 hypertension.
Balancing these limitations, this study has several strengths that lend confidence to the findings: it was a prospective study, which lends support to the evidence of a causal role of OSA in hypertension development; the subjects were from the general population, thus minimizing selection bias; the sample size was large and included a similar proportion of men and women; and the follow-up period was prolonged (7.5 AE 0.8 years).
Conclusions
In summary, the results suggest an association between patients with OSA and the risk of developing stage 2 hypertension in men. Increasing age was a significant factor explaining the presence of hypertension in men and women. Neither symptoms (EDS) nor nocturnal hypoxia was independently associated with the incidence of hypertension.
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